BioLife Solutions Inc. (BLFS) — 分析摘要
BioLife Solutions Inc.（BLFS）的市值为1.37十亿美元，最近一年的营收同比增长了+17.0%。净利润率为-4.8%。当前市盈率为-463.7倍。
核心要点
- 营收同比变化+17.0%
- 净利润率-4.8%
- 市盈率-463.7倍
与ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS板块的其他公司相比，BLFS的营收增长为+17.0%，市盈率为-463.7倍。
BioLife Solutions Inc. (BLFS)
更新 — ET · 来源 POLYGON
红旗与风险提示重点关注
当前存在需要关注的风险信号，应与估值结果一并解读。
营业利润率为 -15.4% — 经营亏损显著
BioLife Solutions Inc is a life sciences company that develops, manufactures, and markets bioproduction products and services that are designed to improve quality and de-risk biologic manufacturing, distribution, and transportation in the cell and gene therapy ("CGT") industry. The company provides solutions such as Cell Processing, Cold Chain, and Thawing. The company generates the majority of its revenue from Cell Processing through the biopreservation product "CryoStor". Geographically the company generates the majority of its revenue from the United States.
行业
ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS
员工人数
155
总部
BOTHELL, WA
Exchange
XNAS
基于 4 年财务数据的系统性竞争优势评估
此评估基于历史财务数据的量化分析，不构成投资建议。护城河评级可能随行业和竞争环境变化。
首版展示近期 SEC Forms 3、4、5 备案活动。尚未解析单笔买入/卖出交易。
资本结构
现金流
免责声明：本站内容不构成投资建议。数据来源于SEC EDGAR和Polygon.io。过往业绩不代表未来表现。投资决策前请自行研究。